Page last updated: 2024-08-24

irinotecan and butylscopolammonium bromide

irinotecan has been researched along with butylscopolammonium bromide in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fujii, H; Iihara, H; Kobayashi, R; Matsuhashi, N; Suzuki, A; Takahashi, T; Yoshida, K; Yoshimi, C	1

Other Studies

1 other study(ies) available for irinotecan and butylscopolammonium bromide

Article	Year
Prophylactic effect of scopolamine butylbromide, a competitive antagonist of muscarinic acetylcholine receptor, on irinotecan-related cholinergic syndrome. Cancer chemotherapy and pharmacology, 2019, Volume: 83, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Butylscopolammonium Bromide; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Irinotecan; Japan; Male; Middle Aged; Muscarinic Antagonists; Neoplasms; Parasympathetic Nervous System; Risk Factors; Syndrome	2019

Article

Year

Prophylactic effect of scopolamine butylbromide, a competitive antagonist of muscarinic acetylcholine receptor, on irinotecan-related cholinergic syndrome.

Cancer chemotherapy and pharmacology, 2019, Volume: 83, Issue:3

Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Butylscopolammonium Bromide; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Irinotecan; Japan; Male; Middle Aged; Muscarinic Antagonists; Neoplasms; Parasympathetic Nervous System; Risk Factors; Syndrome

2019